Abstract

Objective To observe the differences between intravitreal injection of ranibizumab (Lucentis) and triamcinolone (TA) before vitrectomy surgery in the treatment of proliferative diabetic retinopathy (PDR). Methods A total of 61 patients (78 eyes) with PDR diagnosed in our clinic from March 2014 to September 2015 were enrolled and divided into Lucentis group (33 patients, 42 eyes) and TA group (28 patients, 36 eyes). Lucentis group patients received an intravitreal injection of Lucentis before pars plana vitrectomy (PPV), TA group patients received an intravitreal injection of TA. The average operation time, the use of filler and electric coagulation, the change of best corrected visual acuity (BCVA), postoperative bleeding, intraocular pressure (IOP) and central macular thickness (CMT) were comparatively analyzed between the two groups. Results The operation time in the Lucentis group was (46.95±18.16)min, while in the TA group was (66.42±17.76)min, the difference was statistically significant (t=-4.767, P=0.000). Three eyes needed electric coagulation in Lucentis group, eleven eyes in TA group, and the difference was statistically significant (χ2=7.215, P= 0.009). The mean 3 months after surgery logMAR BCVA of Lucentis group and TA group had both improved than their preoperative BCVA (t=6.557, 5.837; P=0.000, P=0.000). The differences of oil silicone use, postoperative bleeding, IOP and CMT between two group were not statistically significant (P >0.05). Conclusions The intravitreal injection of Lucentis and TA before the vitrectomy surgery for PDR are both effective. Lucentis can more significantly decrease intraoperative hemorrhage, reduce electric coagulation, and shorten the operation time, improve the effects of PPV in PDR patients. Key words: Proliferative diabetic retinopathy; Ranibizumab; Triamcinolone; Vitrectomy; Injection of intravitreal

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call